Amgen Inc. (NASDAQ:AMGN) Shares Sold by Curi RMB Capital LLC

Curi RMB Capital LLC cut its stake in Amgen Inc. (NASDAQ:AMGN) by 3.3% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 49,170 shares of the medical research company’s stock after selling 1,681 shares during the period. Curi RMB Capital LLC’s holdings in Amgen were worth $15,843,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the stock. Capital Performance Advisors LLP purchased a new stake in Amgen during the 3rd quarter worth $25,000. Strategic Financial Concepts LLC acquired a new stake in shares of Amgen during the second quarter valued at about $26,000. Hershey Financial Advisers LLC purchased a new stake in shares of Amgen during the second quarter worth about $30,000. nVerses Capital LLC purchased a new stake in shares of Amgen during the second quarter worth about $31,000. Finally, Bbjs Financial Advisors LLC acquired a new position in shares of Amgen in the 2nd quarter valued at approximately $33,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

AMGN has been the topic of several recent analyst reports. Robert W. Baird reaffirmed an “underperform” rating and issued a $215.00 price target on shares of Amgen in a report on Wednesday, September 25th. Jefferies Financial Group reissued a “buy” rating and set a $380.00 target price on shares of Amgen in a report on Tuesday. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a $305.00 price target (down from $310.00) on shares of Amgen in a report on Wednesday, August 7th. Royal Bank of Canada reiterated an “outperform” rating and set a $362.00 price target on shares of Amgen in a research report on Thursday, September 26th. Finally, StockNews.com raised Amgen from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. One analyst has rated the stock with a sell rating, twelve have given a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Amgen has a consensus rating of “Moderate Buy” and an average price target of $333.57.

Amgen Stock Performance

Amgen stock opened at $301.44 on Thursday. Amgen Inc. has a fifty-two week low of $260.52 and a fifty-two week high of $346.85. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96. The company has a market cap of $162.03 billion, a P/E ratio of 38.60, a price-to-earnings-growth ratio of 2.67 and a beta of 0.60. The firm’s 50 day simple moving average is $322.15 and its 200-day simple moving average is $318.15.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.11 by $0.47. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The business had revenue of $8.50 billion during the quarter, compared to analyst estimates of $8.50 billion. During the same period in the prior year, the firm earned $4.96 earnings per share. The firm’s revenue was up 23.2% compared to the same quarter last year. As a group, equities research analysts predict that Amgen Inc. will post 19.51 EPS for the current year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 9th. Investors of record on Monday, November 18th will be paid a $2.25 dividend. The ex-dividend date is Monday, November 18th. This represents a $9.00 annualized dividend and a dividend yield of 2.99%. Amgen’s payout ratio is 115.24%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.